Risperidone transiently worsened behavioral impairments during drug exposure but did not affect the extent of tissue damage or long-term functional outcome. This is consistent with recent work in the Journal by Nathan Herrmann, M.D., F.R.C.P.(C.), et al. (4). Perhaps the alarming reports on risperidone, which could lead to use of nonatypical neuroleptics, should be reconsidered. Previous epidemiological studies (1) have been characterized by a low number of patients, polypharmacy, other diseases, compliance, and/or appropriateness of use. We suggest that additional controlled experimental approaches might better address the safety of psychotropic drugs.